Acute Widespread Rash in a 9-month-old Boy

Your daily dose of the clinical news you may have missed.

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Treatments with the investigational rescue medication achieved clinically effective epinephrine levels faster than intramuscular injection.

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.